Exenatide (revision 1)
Old revision·09:00, 24 Sep 2024·Chromatokid
This is an old revision of this page, as it stood at 09:00, 24 Sep 2024, saved by Chromatokid with the summary start article on the compound. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Exenatide | |
|---|---|
| INN | exenatide |
| Class | GLP-1 receptor agonist |
| Origin | Synthetic exendin-4 |
| First approval | 2005 |
| Compound infobox · conventions | |
Exenatide is a synthetic version of exendin-4, a 39-residue peptide isolated from the venom of the Gila monster, Heloderma suspectum. It shares approximately 53% sequence identity with human Glucagon-like peptide-1 and is a full agonist at the GLP-1 receptor. Approved in 2005, it was the first GLP-1 receptor agonist to reach the market.[1]
Its therapeutic relevance rests on an accident of sequence: exendin-4 carries glycine rather than alanine at position 2, so DPP-4 does not cleave it. No engineering was required to obtain protease resistance — the peptide is naturally resistant, and this is why a venom peptide became a diabetes drug.[1]
References
Categories: